PT-141 (Bremelanotide) vs Oxytocin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Oxytocin
Oxytocin is a natural hormone produced in the hypothalamus, often called the 'love hormone' or 'bonding hormone.' It plays key roles in social bonding, childbirth, lactation, and stress regulation.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | Oxytocin |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Binds to oxytocin receptors in the brain and peripheral tissues. Promotes social bonding, reduces anxiety and stress response, and has various peripheral effects on smooth muscle contraction. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Intranasal: 20-40 IU (international units) for social/anxiolytic effects. Clinical uses (labor induction) require IV administration under medical supervision. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Intranasal spray for behavioral effects. IV only in clinical settings. Sublingual also possible. Best used situationally rather than continuously. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Intranasal: headache, nasal irritation, drowsiness. May cause over-attachment or emotional sensitivity. IV (clinical): uterine hyperstimulation, water retention. |
| Best For |